Our work on a sequencing assay that allows for the screening of “actionable” gene mutations in lymphoid tumors has been published in the Journal of Molecular Diagnostics! This work, which was led by Stacy Hung, establishes the feasibility of capture sequencing on routinely acquired biopsy materials and demonstrates the clinical utility of integrating a lymphoma-specific pipeline into personalized cancer care.